Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fuji
Teva
Chubb
Chinese Patent Office
Farmers Insurance
Medtronic
Cantor Fitzgerald
US Department of Justice

Generated: December 18, 2018

DrugPatentWatch Database Preview

Desvenlafaxine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for desvenlafaxine and what is the scope of desvenlafaxine freedom to operate?

Desvenlafaxine is the generic ingredient in four branded drugs marketed by Alembic Pharms Ltd, Osmotica Pharm Corp, Sun Pharma Global, Teva Pharms Usa, Actavis Labs Fl, Casi Pharms Inc, Lupin Ltd, Mylan Pharms Inc, West-ward Pharms Int, Yichang Humanwell, Zydus Pharms Usa Inc, and Wyeth Pharms Inc, and is included in fourteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for desvenlafaxine. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Synonyms for desvenlafaxine
130198-08-2
93414-04-1
CHEMBL3039565
Desvenlafaxine fumarate
O-Desmethylvenlafaxine fumarate
Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-, (2E)-2-butenedioate (1:1) (salt)
Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-, (E)-2-butenedioate (1:1) (salt)
SCHEMBL3400998
SCHEMBL521350
SQTJDJZCPOSWSC-WLHGVMLRSA-N
Tentative approvals for DESVENLAFAXINE
Applicant Application No. Strength Dosage Form
➤ Sign Up➤ Sign Up100MGTABLET, EXTENDED RELEASE;ORAL
➤ Sign Up➤ Sign Up50MGTABLET, EXTENDED RELEASE;ORAL

US Patents and Regulatory Information for desvenlafaxine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204095-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fuji
Teva
Chubb
Chinese Patent Office
Farmers Insurance
Medtronic
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.